FISC Ventures
VC Fund
New York, United States
FISC Ventures is a VC fund in New York focused on Health Care and Medical. Fisk Ventures is a venture capital firm that serves customers in the United States.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries FISC Ventures invests in
Stages FISC Ventures invests in
Countries FISC Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Stephen L. Rose
|
|||
|
H. Fisk Johnson
|
|||
Investment Focus
Industry
- Health Care 3 (23%)
- Medical 2 (15%)
- Biotechnology 2 (15%)
- Medical Device 2 (15%)
- SaaS 1 (8%)
Stage
- Series C 3 (23%)
- Series D 2 (15%)
- Series A 1 (8%)
- Series B 1 (8%)
- Series E 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Stephen L. Rose
Managing Director
|
Managing Director | Total investments: 7 | Find email | |
|
H. Fisk Johnson
President
|
President | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Senet offers a low cost, long distance sensor network, and high-value SaaS applications on a subscription fee basis to help businesses make fact-based decisions. Senet's cost-effective, highly-scalable network enables companies to capitalize on opportunities in the rapidly growing Machine-to-Machine (M2M) Internet of Things (IoT) landscape. | $16M / Venture - Series Unknown / Sep 22, 2020 | ||
| MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order toprevent vision loss. | $38.7M / Series D / Mar 04, 2019 | ||
| Stratos Genomics develops sequencing by expanding the single-molecule detection process that allows whole-genome sequencing. The company was founded in 2007 and is based in Seattle, Washington. | $20M / Series B / Jan 08, 2018 | ||
| MacuLogix focuses on detecting and tracking age-related macular degeneration. It leverages the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professionals to detect, monitor, and start treating AMD three years before it can be seen in order toprevent vision loss. | $5M / Series C / Oct 16, 2015 | ||
| Senet offers a low cost, long distance sensor network, and high-value SaaS applications on a subscription fee basis to help businesses make fact-based decisions. Senet's cost-effective, highly-scalable network enables companies to capitalize on opportunities in the rapidly growing Machine-to-Machine (M2M) Internet of Things (IoT) landscape. | $18M / Series A / Jun 22, 2015 | ||
| Stratos Genomics develops sequencing by expanding the single-molecule detection process that allows whole-genome sequencing. The company was founded in 2007 and is based in Seattle, Washington. | $15M / Series B / Jun 16, 2015 | ||
| Stratos Genomics develops sequencing by expanding the single-molecule detection process that allows whole-genome sequencing. The company was founded in 2007 and is based in Seattle, Washington. | $10M / Series B / May 13, 2014 | ||
| Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conductingpilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California | $15M / Series G / Jun 28, 2013 | ||
| Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conductingpilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California | $15.3M / Series F / Mar 15, 2012 | ||
| Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conductingpilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California | $19M / Series E / Jan 12, 2009 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does FISC Ventures invest in?
FISC Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series D stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact FISC Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at FISC Ventures?
The team at FISC Ventures includes Stephen L. Rose (Managing Director) and H. Fisk Johnson (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
